Brief: Entrada Therapeutics Reports Q1 2023 Financial Results
10/05/2023 13:32
May 10 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL
RESULTS
* ENTRADA THERAPEUTICS INC - $412 MILLION IN CASH, CASH
EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2023
* ENTRADA THERAPEUTICS INC - CASH RUNWAY INTO SECOND HALF OF
2025
* ENTRADA THERAPEUTICS INC- QTRLY LOSS PER SHARE $0.21
Source text for Eikon: ID:nGNXbBbRML
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview